However, mice received with T cell transfer plus FasL and/or PD‐L2 blocking antibody‐treated TCN showed reduced tumor volumes and disease progression at each measurement time point from day 22 (Figure 7A), indicating a vital role of FasL+PD‐L2+ neutrophils in assisting tumors in vivo. The gene discussed is PDCD1LG2; the disease is neoplasm.